Mechanisms of Action of Tranexamic Acid, Vitamin K, and Ethamsylate
Tranexamic Acid
Tranexamic acid is a synthetic lysine analogue that competitively inhibits plasminogen activation, thereby preventing fibrinolysis and stabilizing formed blood clots. 1
Detailed Mechanism:
- Primary action: Binds reversibly to lysine binding sites on plasminogen molecules, particularly the high-affinity lysine site (Kd = 1.1 μmol/L) involved in fibrin binding 1
- Effect on fibrinolysis: Displaces plasminogen from the fibrin surface, preventing its conversion to plasmin and subsequent dissolution of the fibrin matrix 2
- Tissue distribution: Distributed throughout all tissues with a plasma half-life of approximately 120 minutes 2
- Excretion: More than 95% excreted unchanged in urine via glomerular filtration 1
The antifibrinolytic concentration remains in tissues for approximately 17 hours and in serum for 7-8 hours 1. At therapeutic concentrations (up to 10 mg/mL), tranexamic acid does not affect platelet count, coagulation time, or various coagulation factors 1.
Beyond Antifibrinolysis:
Recent evidence demonstrates that tranexamic acid has additional mechanisms beyond simple fibrinolysis inhibition, including anti-inflammatory effects, endothelial protection, and suppression of melanogenesis 3. However, the primary clinically relevant mechanism remains its antifibrinolytic action through plasminogen inhibition.
Vitamin K
Vitamin K functions as an essential cofactor for the post-translational carboxylation of glutamic acid residues on vitamin K-dependent coagulation factors, rendering them functionally active.
Detailed Mechanism:
- Vitamin K cycle: Vitamin K1 (from dietary sources) is reduced to vitamin K hydroquinone (KH2) by a warfarin-resistant reductase 4
- Carboxylation step: Vitamin KH2 is oxidized to vitamin K epoxide during the carboxylation of glutamic acid residues on coagulation factors II, VII, IX, and X, as well as anticoagulant proteins C and S 4, 5
- Recycling: Vitamin K epoxide is reduced back to vitamin K1 by vitamin K epoxide reductase (the target of warfarin) 4
- Functional activation: The gamma-carboxylation of glutamate residues is essential for calcium binding and subsequent activation of these clotting proteins 5
The mechanism involves a dioxetane intermediate and explains the incorporation of oxygen atoms into vitamin K oxide during enzymatic carboxylation 5. When vitamin K is deficient or its cycle is blocked (as with warfarin), these coagulation factors are produced but remain functionally inactive.
Ethamsylate (Etamsylate)
Ethamsylate is a hemostatic agent that acts primarily by increasing capillary resistance and platelet adhesion, though its exact mechanism remains less well-defined than tranexamic acid or vitamin K.
Detailed Mechanism:
Based on available evidence, ethamsylate appears to:
- Enhance capillary wall stability: Reduces capillary fragility and permeability
- Promote platelet adhesion: Improves platelet function at the site of vascular injury
- Does NOT act as an antifibrinolytic: Unlike tranexamic acid, it does not inhibit plasminogen or fibrinolysis 6
Clinical Context:
A randomized controlled trial comparing ethamsylate to tranexamic acid in cesarean section found that while both reduced blood loss compared to placebo, ethamsylate was less effective than tranexamic acid but could serve as an alternative in patients with contraindications to tranexamic acid 6. This suggests ethamsylate works through a different, likely less potent mechanism focused on vascular integrity rather than fibrinolysis inhibition.
Key Distinctions:
- Tranexamic acid: Antifibrinolytic—prevents clot breakdown by inhibiting plasminogen activation
- Vitamin K: Procoagulant cofactor—enables synthesis of functional clotting factors
- Ethamsylate: Hemostatic—stabilizes capillaries and enhances platelet function
These three agents work at completely different points in the hemostatic process and are not interchangeable. Tranexamic acid has the strongest evidence base for reducing bleeding and mortality in trauma and surgical settings 2, 7.